Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Open-label, Dose-Finding Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Subjects With Newly Diagnosed Glioblastoma

NCT04324840 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT04324840
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04324840 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Open-label, Dose-Finding Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Subjects With Newly Diagnosed Glioblastoma
Lead sponsor
Celgene
Phase
Phase 1
Overall status
Terminated
Start date
July 10, 2020
Completion date
July 9, 2024
Enrollment
184 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma